Synthetic Biology in T-cell Engineering Research DOI

Irmak Yılmazer

Next frontier., Journal Year: 2024, Volume and Issue: 8(1), P. 95 - 95

Published: Nov. 8, 2024

Synthetic biology has emerged as a transformative discipline, enabling precise genetic and functional reprogramming of cellular systems. In T-cell engineering, it offers groundbreaking potential to revolutionize immunotherapy by endowing T cells with enhanced specificity, adaptability, resilience against complex diseases such cancer autoimmune disorders. By integrating advanced genome-editing tools like CRISPR-Cas9 modular synthetic constructs, researchers can design bespoke functionalities, tunable antigen recognition, controlled cytokine release, resistance immunosuppressive tumor microenvironments. This approach not only overcomes the limitations conventional therapies but also facilitates development novel therapeutic paradigms, including "smart" systems capable sensing responding dynamic biological cues. Furthermore, circuits allow for incorporation logic-gated mechanisms minimize off-target effects enhance precision. Despite these advancements, challenges remain in optimizing safety, scalability, regulatory compliance. research aims explore intersection highlighting cutting-edge methodologies, applications, emerging trends. addressing current envisioning future possibilities, this work seeks contribute growing body knowledge driving toward clinical industrial breakthroughs immunotherapy.

Language: Английский

Boosting CAR-T cell therapy through vaccine synergy DOI Creative Commons
Yan-Ruide Li,

Zibai Lyu,

Xinyuan Shen

et al.

Trends in Pharmacological Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematological cancers. However, achieving comparable success in solid tumors remains challenging. Factors contributing to these limitations include scarcity of tumor-specific antigens (TSAs), insufficient CAR-T infiltration, and immunosuppressive tumor microenvironment (TME). Vaccine-based strategies are emerging as potential approaches address challenges, enhancing expansion, persistence, antitumor efficacy. In this review, we explore diverse vaccine modalities, including mRNA, peptide, viral vector, dendritic (DC)-based vaccines, their roles augmenting responses. Special focus is given recent clinical advancements combining mRNA-based vaccines with genitourinary addition, discuss crucial considerations optimizing dosing, scheduling, delivery maximize synergy, aiming refine combination strategy improve efficacy safety.

Language: Английский

Citations

2
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment DOI Creative Commons
Thuỳ Anh Bùi, Haoqi Mei, Rui Sang

et al.

EBioMedicine, Journal Year: 2024, Volume and Issue: 106, P. 105266 - 105266

Published: Aug. 1, 2024

The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and high manufacturing cost associated with current ex vivo CAR products, alternative strategies to produce cells directly body have been developed recent years. These involve direct infusion of genes via engineered nanocarriers or viral vectors generate situ. This review offers comprehensive overview advancements development cell-targeted generation Additionally, it identifies challenges method potential these issues.

Language: Английский

Citations

15
Frontiers in CAR-T cell therapy for autoimmune diseases DOI Creative Commons
Yan-Ruide Li,

Zibai Lyu,

Yuning Chen

et al.

Trends in Pharmacological Sciences, Journal Year: 2024, Volume and Issue: 45(9), P. 839 - 857

Published: Aug. 14, 2024

Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has demonstrated significant success in treating cancers. The potential of CAR-T cells is now being explored the context autoimmune diseases. Recent clinical trials have shown sustained and profound elimination autoreactive B by cells, leading to promising disease control with minimal safety concerns. These encouraging results inspired further investigation into applications for a broader range diseases development advanced products improved efficacy safety. In this review, we discuss mechanisms which target conditions, summarize current preclinical models, highlight ongoing trials, including design, outcomes, challenges. Additionally, limitations future directions treatment

Language: Английский

Citations

13
In vivo vectorization and delivery systems for gene therapies and RNA-based therapeutics in oncology DOI

Julie Schock Vaiani,

Mans Broekgaarden, Jean‐Luc Coll

et al.

Nanoscale, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Gene and RNA-based therapeutics represent a promising frontier in oncology, enabling targeted modulation of tumor-associated genes proteins. This review explores the latest advances payload vectorization delivery systems developed for vivo cancer treatments. We discuss viral non-viral organic particles, including lipid based nanoparticles polymeric structures, effective transport plasmids, siRNA, self-amplifying RNA therapeutics. Their physicochemical properties, strategies to overcome intracellular barriers, innovations cell-based carriers engineered extracellular vesicles are highlighted. Moreover, we consider oncolytic viruses, novel capsid modifications, approaches that refine tumor targeting immunomodulation. Ongoing clinical trials regulatory frameworks guide future directions emphasize need safe, scalable production. The potential convergence these with combination therapies paves way toward personalized medicine.

Language: Английский

Citations

1
Defining immune reset: achieving sustained remission in autoimmune diseases DOI
Tobias Junt, Thomas Calzascia,

Elisabetta Traggiai

et al.

Nature reviews. Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: March 5, 2025

Language: Английский

Citations

1
Non-viral vectors for chimeric antigen receptor immunotherapy DOI
Sandy Tretbar, Joel G. Rurik,

Even H Rustad

et al.

Nature Reviews Methods Primers, Journal Year: 2024, Volume and Issue: 4(1)

Published: Oct. 10, 2024

Language: Английский

Citations

4
Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids DOI Creative Commons

Johannes Bader,

Finn Brigger,

Jean‐Christophe Leroux

et al.

Advanced Drug Delivery Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 115461 - 115461

Published: Oct. 1, 2024

Language: Английский

Citations

4
Leveraging T cell-specific fusogenicity of HIV for in vivo mRNA delivery to produce human CAR-T cells DOI Creative Commons
Yue Wang, Min Yang,

Bao-Yue Zhang

et al.

Published: March 1, 2025

Language: Английский

Citations

0
In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines DOI Open Access
Sikun Meng,

Tomoaki Hara,

Yutaka Miura

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3119 - 3119

Published: March 28, 2025

Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized cancer immunotherapy but continues to face significant challenges that limit its broader application, such as targeting, the tumor microenvironment, and persistence, especially in solid tumors. Meanwhile, global implementation of mRNA vaccines during COVID-19 pandemic highlighted transformative potential lipid nanoparticle (LNP) technologies. These innovations, characterized by their swift development timelines, precise design, efficient delivery mechanisms, provide a promising framework address some limitations CAR-T therapy. Recent advancements, including mRNA-based CAR engineering optimized LNP delivery, have demonstrated capacity enhance efficacy, particularly context This review explores how mRNA-LNP technology can drive vivo engineered therapies current discusses future directions, advancements optimization, strategies for improving functionality safety. By bridging these technological insights, may evolve into versatile accessible treatment paradigm across diverse oncological landscapes.

Language: Английский

Citations

0
Strategies for Altering Delivery Technologies to Optimize CAR Therapy DOI Open Access
Lili Cao, Yingying Liu, Guimei Lin

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3206 - 3206

Published: March 30, 2025

Chimeric antigen receptor (CAR) T-cell therapy has been proven to be an effective strategy for the treatment of hematological malignancies. At present, how prepare CAR-T cells efficiently, quickly, and safely is one urgent problems solved. The durability activity engineered T in solid tumors need further improved, penetrating tumor microenvironment also needs improved. In addition, although mainly caused by biology are being solved, manufacturing mode process still improved ensure that cell can widely used. This paper summarizes some strategies improve efficacy cells.

Language: Английский

Citations

0